1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Biosimilar (Insulin) - Competitive Landscape and Market & Pipeline Analysis, 2016

DelveInsight’s, “Biosimilar (Insulin) - Competitive Landscape and Market & Pipeline Analysis, 2016” discusses the global insulin biosimilar industry. Report analyzes that Insulin and Insulin Biosimilars holds a future scope and potential in the market. It highlights the market trends, regulatory requirements for US and EU and key domestic players.

Report provides an insight on Insulin Biosimilars that are under development for Type 1 and Type 2 Diabetes with an insight on the Epidemiology of the disease. It provides detailed information on the 11 Insulin Biosimilar that are in pipeline.

It analyses Insulin Biosimilar industry and discusses the key market trends, major players, market assessment of 6 marketed insulin and the types of insulin with the length activity available in market. Report provides an update on the recent collaborations occurring in the insulin biosimilar market and the companies looking for partnership for the same.


Scope:

- Coverage of global insulin biosimilar under development across the globe
- Sales forecast for marketed insulin from 2015 to 2017
- Detailed information on product description and related stage of development, the mode of therapy, mechanism of action, development partner and technology information.
- The report discusses the biosimilar regulatory landscape of various markets including developed markets of the US and EU
- Report analyses the types of insulin under development with respect to their market share and length of activity


Reason to Buy

- The insulin biosimilar report covers complete Pipeline intelligence and understanding over therapeutics development for insulin market.
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of insulin under development
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding the insulin biosimilar pipeline in-depth
- Identifying the upcoming leaders in the insulin biosimilar market in the coming year

Table Of Contents

Biosimilar (Insulin) - Competitive Landscape and Market and Pipeline Analysis, 2016

Illustrative Table of contents
Executive Summary
Biosimilar
History of Insulin and Insulin Biosimilar Development
Regulatory Pathways in US and EU
Illustration of the Originator and Biosimilar Development
Major Indication
Epidemology
Complications Associated with Diabetes
Diagnosis of Diabetes
Analysis
Clinical Trials
Technology
Market Assessment
Market Trends
Drivers
Barriers
Historical Sales Data for the Marketed Drugs
Forecasted Sales Data for the Marketed Drugs
Major Competitors
Types of insulin and length of activity
Pipeline Therapeutics
Therapeutics under Development by Companies
Therapeutic Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Dormant Products
Product Development Activities
Companies involved in Therapeutics Development

Appendix
Methodology
Consulting Services
About DelveInsight
Contact Us
Disclaimer
List of Tables
Table 1:Marketed Insulin Details, 2016
Table 8: Historical Global Sales of Marketed Insulin Analogs 2011-2014 (in million USD), 2016
Table 9: Forecasted Global Sales of Marketed Insulin Analogs 2015-2017 (in million USD), 2016
Table 10:Number of Products Under Development for Insulin Biosimilars,2016
Table 11: Number of Products under Development by Companies,2016
Table 12: Late Stage Products (Phase III and Filed), 2016
Table 13: Early Stage Products (Phase I and IND),2016
Table 14: Pre-Clinical and Discovery Products, 2016
Table 15: Assessment by Monotherapy Products, 2016
Table 16: Assessment by Combination Products, 2016
Table 17: Assessment by Route Of Administration, 2016
Table 18:Assessment by Stage and Route Of Administration, 2016
Table 19: Assessment by Molecule Type, 2016
Table 20: Assessment by Stage and Molecule Type, 2016
Table 21: Dormant Products, 2016
List of Figures
Figure 1: Number of products with ongoing and completed clinical trials, 2016
Figure 2: Number of products with ongoing and completed clinical trials, 2016
Figure 3: Number of products in clinical trials with companies, 2016
Figure 4: Number of technology associated with the companies, 2016
Figure 5: Number of Product with Insulin Biosimilar Technology, 2016
Figure 6: Historical Global Sales of Marketed Insulin Analogs 2011-2014 (in million USD), 2016
Figure 7: Forecasted Global Sales of Marketed Insulin Analogs 2015-2017 (in million USD), 2016
Figure 8: Types of Insulin Biosimilar Under Development, 2016
Figure 9: Number of different type of Insulin Biosimilar and Company, 2016
Figure 10: Number of Products under Development for Insulin Biosimilars, 2016
Figure 11: Late Stage Products (Phase III), 2016
Figure 12: Mid Stage Products (Phase II),2016
Figure 13: Early Stage Products (Phase I and IND), 2016
Figure 14:Pre-Clinical and Discovery Products, 2016
Figure 15: Assessment by Monotherapy Products, 2016
Figure 16: Assessment by Combination Products, 2016
Figure 17: Assessment by Route of Administration, 2016
Figure 18: Assessment by Stage and Route of Administration, 2016
Figure 19: Assessment by Molecule Type, 2016
Figure 20: Assessment by Stage and Molecule Type, 2016
Figure 21: Dormant Products, 2016

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Type 2 Diabetes Mellitus: KOL Insight 2016

Type 2 Diabetes Mellitus: KOL Insight 2016

  • $ 8085
  • Industry report
  • September 2016
  • by Firstword Pharma

Can top-ranked GLP1 agonists move out of the third-line setting? GLP1 agonists may be the top-ranked type 2 diabetes mellitus (T2DM) treatment according to the American Association of Clinical Endocrinologists ...

European Market Report for Modern Insulin 2016 - MedCore

European Market Report for Modern Insulin 2016 - MedCore

  • $ 5995
  • Industry report
  • September 2016
  • by iData Research, Inc.

The European modern insulin market can be segmented by insulin type, yielding three segments: long-acting insulin, rapid-acting insulin and premixed insulin. In 2015, the largest segment in the total modern ...

US Market Report for Insulin 2017 - MedCore

US Market Report for Insulin 2017 - MedCore

  • $ 5495
  • Industry report
  • November 2016
  • by iData Research, Inc.

Description The U.S. insulin market can be segmented by insulin type, yielding four segments: long-acting insulin, rapid-acting insulin, premixed insulin and human insulin. In 2016, the largest segment ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.